Mikhail Kolonin, Ph.D.
Director, Center for Metabolic and Degenerative Diseases
Harry E. Bovay, Jr. Distinguished University Chair in Metabolic Disease Research
Mikhail Kolonin, Ph.D. received his doctorate from Wayne State University where he has pioneered the concept of expressing peptides designed to disrupt protein interactions in live animals. As a post-doctoral fellow at M.D. Anderson Cancer Center, he has optimized in vivo phage display technology to isolate differentially expressed cell surface molecules by integrating molecular biology with bioinformatics. This work, first initiated in the mouse model and then translated to screens in cancer patients, has led to tissue-specific cell surface protein interactions now pursued as therapy targets. Dr. Kolonin invented an approach to obesity reversal through directed ablation of white fat vasculature with a peptide-directed drug Adipotide. Current research in the Laboratory converges on stem cells, obesity, metabolism, and cancer. His studies, based on the analysis of clinical specimens and mouse models, focus is on the role of fat tissue cells in healthy aging and disease. Dr. Kolonin and colleagues have discovered the phenomenon of adipose cell mobilization and trafficking to tumors and the stimulatory effect of adipose stromal cells on cancer progression. These findings have provided new insights on the association between obesity and cancer. The group has reported an agent designed to target white adipocyte progenitors, which is being pre-clinically tested for obesity and cancer therapy. Recent research has focused on the role of brown adipocyte progenitors in maintenance of healthy metabolism.
- Wanqiao Cao: Research Technician
- Alexis Daquinag: Senior Research Scientist
- Zhanguo Gao: Research Scientist
- Fei Su: Research Scientist